Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antirheumatic Agents | 10 | 2020 | 3023 | 1.86 | Why? |
| Giant Cell Arteritis | 4 | 2020 | 137 | 1.56 | Why? |
| Rheumatic Diseases | 6 | 2020 | 2675 | 1.41 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 3 | 2020 | 235 | 1.30 | Why? |
| Arthritis | 2 | 2020 | 288 | 1.13 | Why? |
| Systemic Vasculitis | 3 | 2019 | 74 | 1.05 | Why? |
| Optic Neuropathy, Ischemic | 1 | 2020 | 23 | 0.84 | Why? |
| Granulomatosis with Polyangiitis | 3 | 2020 | 161 | 0.76 | Why? |
| Histidine-tRNA Ligase | 1 | 2017 | 4 | 0.73 | Why? |
| Blindness | 1 | 2020 | 130 | 0.72 | Why? |
| Spondylitis, Ankylosing | 2 | 2018 | 231 | 0.71 | Why? |
| Myositis | 2 | 2017 | 185 | 0.69 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.60 | Why? |
| Arthritis, Rheumatoid | 3 | 2018 | 2043 | 0.60 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2018 | 2483 | 0.50 | Why? |
| Biological Therapy | 1 | 2017 | 456 | 0.47 | Why? |
| Delayed Diagnosis | 1 | 2020 | 1529 | 0.41 | Why? |
| Rheumatology | 1 | 2020 | 1213 | 0.39 | Why? |
| Lung Diseases, Interstitial | 1 | 2017 | 1476 | 0.32 | Why? |
| Immunosuppressive Agents | 4 | 2020 | 6331 | 0.30 | Why? |
| Pharmaceutical Preparations | 1 | 2020 | 1897 | 0.29 | Why? |
| Periodicals as Topic | 1 | 2018 | 1492 | 0.29 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.26 | Why? |
| Rituximab | 3 | 2020 | 1096 | 0.25 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2020 | 1454 | 0.21 | Why? |
| Takayasu Arteritis | 2 | 2018 | 83 | 0.20 | Why? |
| Cryoglobulinemia | 2 | 2018 | 144 | 0.19 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.19 | Why? |
| Uveitis, Anterior | 1 | 2019 | 71 | 0.18 | Why? |
| Neuroanatomy | 1 | 2017 | 20 | 0.18 | Why? |
| Temporal Arteries | 1 | 2017 | 35 | 0.17 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2017 | 107 | 0.16 | Why? |
| Spondylarthritis | 1 | 2019 | 174 | 0.16 | Why? |
| Arthritis, Psoriatic | 2 | 2019 | 625 | 0.15 | Why? |
| Muscular Diseases | 1 | 2021 | 392 | 0.15 | Why? |
| Abatacept | 1 | 2017 | 192 | 0.15 | Why? |
| Fibromyalgia | 1 | 2017 | 174 | 0.14 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 176 | 0.14 | Why? |
| Cardiovascular Diseases | 1 | 2019 | 11497 | 0.14 | Why? |
| Genotyping Techniques | 1 | 2017 | 360 | 0.13 | Why? |
| Methotrexate | 1 | 2017 | 471 | 0.12 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.12 | Why? |
| Humans | 26 | 2021 | 930598 | 0.12 | Why? |
| Imaging, Three-Dimensional | 1 | 2017 | 680 | 0.12 | Why? |
| Video Recording | 1 | 2017 | 786 | 0.11 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Biological Products | 2 | 2018 | 2331 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.08 | Why? |
| Italy | 3 | 2020 | 38444 | 0.08 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.07 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3633 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.07 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.07 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Aged | 5 | 2020 | 215776 | 0.06 | Why? |
| Male | 8 | 2020 | 367725 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Education, Medical, Graduate | 1 | 2017 | 2082 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Female | 8 | 2020 | 380317 | 0.06 | Why? |
| India | 1 | 2020 | 11875 | 0.06 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Middle Aged | 5 | 2020 | 270681 | 0.05 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.05 | Why? |
| Prognosis | 3 | 2017 | 32490 | 0.05 | Why? |
| HLA-B27 Antigen | 1 | 2019 | 48 | 0.05 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.05 | Why? |
| Microscopic Polyangiitis | 1 | 2018 | 31 | 0.05 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Churg-Strauss Syndrome | 1 | 2018 | 61 | 0.04 | Why? |
| Biopsy | 2 | 2017 | 2811 | 0.04 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Vincristine | 1 | 2017 | 89 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 94 | 0.04 | Why? |
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2017 | 140 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| Cyclophosphamide | 1 | 2017 | 387 | 0.04 | Why? |
| Skull Base | 1 | 2017 | 246 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 9335 | 0.04 | Why? |
| Doxorubicin | 1 | 2017 | 313 | 0.03 | Why? |
| Disability Evaluation | 1 | 2018 | 671 | 0.03 | Why? |
| Adult | 4 | 2020 | 244371 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Prednisone | 1 | 2017 | 652 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.02 | Why? |
| Educational Measurement | 1 | 2017 | 930 | 0.02 | Why? |
| Health Surveys | 1 | 2020 | 2841 | 0.02 | Why? |
| Learning | 1 | 2017 | 1181 | 0.02 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Psoriasis | 1 | 2019 | 1739 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.02 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Students, Medical | 1 | 2017 | 4032 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |